Population‐based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women
Open Access
- 28 November 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 131 (6) , 1388-1395
Abstract
To optimize HPV vaccination implementation at the population‐level in China, data are needed on age‐specific HPV 16, 18, 6 and 11 prevalence. This cross‐sectional, population‐based study evaluated the age‐ and type‐specific HPV 16, 18, 6 and 11 prevalence of DNA and serum antibodies among women in China. From July 2006 to April 2007, 17–54 year old women from three rural provinces (Xinjiang, Shanxi and Henan) and two cities (Beijing and Shanghai) provided cervical exfoliated cells for HPV DNA and liquid‐based cervical cytology (SurePath). High‐ and low‐risk HPV types were detected with HC‐II (Qiagen), with genotyping of HPV‐positive samples using Linear Array (Roche). HPV 16, 18, 6 and 11 serum antibodies were detected using a Luminex‐based, competitive immunoassay (Merck). A total of 4,206 women with DNA and serum antibody results were included. HPV 16 DNA prevalence peaked in women aged 30–34 (4.2%) and 45–49 yr (3.8%), while HPV 18 DNA prevalence peaked at ages 40–44 yr (1.3%). Most women were dually DNA and serum antibody negative: HPV 16 (92.2%), 18 (97.2%), HPV 16 and 18 (90.2%), 6 (92.0%), 11 (96.6%), 6 and 11(89.9%) and HPV 16, 18, 6 and 11 (82.5%). Future national HPV vaccination programs in China should target younger women due to increased exposure to HPV types 16, 18, 6 and 11 with increasing age. Cumulative exposure of HPV may be underreported in this population, as cross‐sectional data do not accurately reflect exposure to HPV infections over time.Keywords
This publication has 44 references indexed in Scilit:
- Detection of HPV types and neutralizing antibodies in Gansu province, ChinaJournal of Medical Virology, 2009
- Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global ReviewJournal of Adolescent Health, 2008
- Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trialsCurrent Medical Research and Opinion, 2008
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult WomenPediatrics, 2006
- Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical SamplesJournal of Clinical Microbiology, 2006
- Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacyInternational Journal of STD & AIDS, 2006
- Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based studyBritish Journal of Cancer, 2004
- Shanxi Province Cervical Cancer Screening Study: A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical NeoplasiaGynecologic Oncology, 2001